Possibly the biggest news this week comes from the schizophrenia space, where AbbVie’s emraclidine failed two mid-stage ...

Shares of AbbVie Inc. ABBV inched 0.60% higher to $201.68 Tuesday, on what proved to be an all-around great trading session ...

The new facility aims to give residents on the South Side better access to cancer care, while also attracting patients from across the region and beyond.

The community element of this prize makes it highly appealing to enter as it promotes discussions about belonging to ...

But the vast majority of six-figure roles are in-person jobs, and experts believe it will remain that way in the long term.

AbbVie (NYSE:ABBV) has once again raised its full-year outlook on soaring demand for its newer immunology medicines, Skyrizi and Rinvoq. The North Chicago, Illinois-based pharma giant now expects ...

(Reuters) -AbbVie raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter earnings, ...

a Represents net earnings attributable to AbbVie Inc. Acquisition and integration costs primarily reflect integration costs related to the Allergan acquisition, including a one-time gain of $169 ...

LATEST NEWS 05:00 How to pick the life insurance policy that’s right for you 05:00 Dublin AI start-up Glitch set to launch online ad platform 05:00 Movers & Shakers: MSD Ireland, Edelman, Ergo, Fáilte ...

Credit: Art_Photo/Shutterstock. AbbVie has entered a definitive agreement to acquire all outstanding equity of Aliada Therapeutics in a $1.4bn cash deal. The deal will include Aliada’s lead ...

AbbVie, with a market value of about a $330 billion ... Retail & Consumercategory Booking.com could cut jobs as part of reorganization plan 10:09 AM UTC Autos & Transportationcategory Exclusive ...

AbbVie has agreed to buy Aliada Therapeutics, a biotechnology company backed by Johnson & Johnson, for $1.4 billion in cash in a deal that adds a potential therapy for Alzheimer’s disease to ...